About DAUNTLESS BIOTHERAPEUTICS, INC.
Dauntless Biotherapeutics is a private preclinical oncology company focused on developing an Antibody Drug Conjugate (ADC) to treat cancers of unmet need. The company is currently conducting a seed round to raise capital for lead optimization and pre-IND studies.
Antibody Drug Conjugate (ADC) developmentLead optimizationIn vivo studiesNon-GLP toxicity studiesPreparation for IND filing
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to DAUNTLESS BIOTHERAPEUTICS, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.